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Abstract
Background: Hydroxyurea (HU) has been demonstrated to be efficacious in reducing complications in individuals
with sickle cell anemia (SCA) but poor adherence is a barrier. Directly Observed Therapy (DOT) has been shown to
improve adherence in various chronic diseases but there is limited data in adults with SCA.
Methods and design: To examine the effect of mobile-directly observed therapy (mDOT) on adherence to HU
(mDOT-HuA) in adults with SCA at Muhimbili National Hospital in Tanzania. The mDOT-HuA study is a single centre,
prospective, randomized, open label clinical trial. One-hundred individuals with SCA with haemoglobin SS
genotype, aged ≥18 years, living in Dar es Salaam, able and willing to record and submit videos electronically
will be included. Participants will be divided into two treatment arms; 50 in the standard monitoring (SM) arm will
receive mobile phones and fixed dose HU therapy with standard monitoring; 50 in the mDOT arm will receive
mobile phones, fixed dose HU therapy with standard monitoring and a mobile directly observed web based
medication adherence monitoring system. The primary outcome is the proportion of participants achieving ≥80 %
HU adherence compared between the two arms as assessed through medication possession ratio at the end of
3 months of treatment. REDCap, an open source software application will be used to collect data using clinical
research forms. The proportions of adherence in the two arms will be compared by Fisher’s exact test. Analysis of
outcomes will have performed by both the intention-to treat and per-protocol methods.
Discussion: Should this study become sucessful, it will have the potential for the development of novel strategies for
improving HU adherence in SCA.
Trial registration: ClinicalTrials.gov Identifier: NCT02844673, registered on 25tht July 2016 (retrospectively registered).
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Background
In Tanzania, sickle cell anemia (SCA) is a major public
health priority; reports show that births of individuals with
SCA are estimated to be 8000–11,000 annually [1]. It is
associated with significant morbidity caused by pain crises,
acute chest syndrome, stroke, pulmonary hypertension,
leg ulcers and irreversible organ damage. There is a high
burden of SCA in Sub-Saharan Africa with high mortality
rate especially in children under 5 years of age [2]. Devel-
oped countries account for less than 8 % of the disease
burden due to interventions such as neonatal screening,
pneumococcal vaccination, prophylactic penicillin treat-
ment and hydroxyurea (HU) treatment, thus reducing
mortality and morbidity and increasing survival rate [2, 3].
HU, the only disease modifying therapy for SCA, has
been demonstrated to be efficacious in reducing com-
plications such as pain crisis and acute chest syndrome
and improving survival [4]. HU works primarily by
inducing fetal hemoglobin in patients with SCA. Other
hematological parameters routinely affected by the use of
HU are the mean corpuscular volume, which tends to
increase, and the leukocyte and platelet counts, which are
expected to decrease [5]. The main clinical outcome of HU
use is a reduction of approximately 50 % in the incidence
of vaso-occlusive crisis and acute chest syndrome, a reduc-
tion in the number of transfusions received by the patient
and an improvement in survival [6, 7].
In spite of its significant benefits, HU is, unfortunately
vastly underutilized and poorly adhered to because of
barriers at the health care system, provider, treatment,
socioeconomic, and patient level [8]. Studies conducted in
resource-rich settings to assess HU adherence and
compliance have shown poor visit and medication
adherence measured by pill count, provider reports and
pharmacy refills [9–13]. In sub-Saharan Africa HU use has
been further limited due to additional barriers related to
the relatively high cost of the drug, scarce availability and
local challenges related to the monitoring of side effects.
To date, there are no studies documenting adherence to
HU in sub-Saharan Africa. The main critical gap in
knowledge and research about HU adherence and safety is
how to assess and tailor interventions according to
individual level barriers to adherence and achieve
effectiveness of HU in real world situations [14], especially
where the environmental factors and adherence assess-
ment techniques that may impact HU compliance are
significantly different from those in the developed coun-
tries. Details of previous studies reporting HU adherence
in SCA are summarized in Table 1.
Directly observed therapy (DOT) has been shown to
improve adherence in multiple clinical trials in diseases
such as Tuberculosis (TB) [15] and HIV infection [16].
DOT is more than supervised pill swallowing; it is also a
means to provide support and education. Universal
DOT for tuberculosis is reported to be associated with a
decrease in the acquisition and transmission of resistant
tuberculosis [15]. DOT for HIV had shown to have a
significant effect on virology, immunologic, and adher-
ence outcomes, although its efficacy was not supported
when restricting analysis to randomized controlled trials
[16]. DOT for HIV shows greatest treatment effect when
targeting individuals with greater risk of non-adherence
and when delivering the intervention that maximizes
participant convenience and provides enhanced adher-
ence support [16]. Some recent meta analyses [17] have
raised questions about the cost-effectiveness of DOT in
TB and HIV suggesting that there is a greater need for
randomized clinical trials of these approaches.
The use of videophone technology may be a cost-
effective alternative to in-home directly observed admin-
istration of medications, particularly when long term or
life-long therapy are needed, as in the case of HU in
SCA [15, 16]. Creary et al., 2014 [3]. reported that
electronic DOT is feasible and acceptable and can
achieve high HU adherence in a pilot pediatric study in
the United States. Further studies are, however, needed
to confirm if electronic DOT can improve HU adherence
[15–17], especially in the developing countries.
In the study presented herein, we will evaluate the level
of adherence, efficacy and safety of fixed dose HU with or
without mDOT in adult HbSS patients at Muhimbili
National Hospital (MNH) in Tanzania. The study has the
potential for the development of novel strategies for
improving HU adherence in SCA.
Methods
Study design
The mobile-directly observed therapy (mDOT) on adher-
ence to HU (mDOT-HuA) study is an investigator-
initiated, single centre, prospectively designed, randomized,
open label phase 4 clinical trial. The study will have four
stages: enrolment, pre-treatment follow up, treatment and
post-treatment follow up (Fig. 1). Enrolment (2 months)
will involve inviting each participant meeting the inclusion
criteria below. After each participant has been enrolled, he/
she will enter a 3-month pre-treatment follow-up period
during which baseline data will be collected. At the end of
this period, all patients will be re-screened for eligibility and
all those still eligible will be randomized to either arm. After
the treatment period, all participants will enter a 2-month
post treatment period when they will stop drug intake but
continue to be on standard monitoring. Details of the trial
design and stages are summarized in the schematic diagram
below (Fig. 1).
Primary and secondary endpoints
The primary endpoint will be the proportion of partici-
pants achieving ≥80 % HU adherence as assessed through
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medication possession ratio (MPR) at the end of 3 months
of HU treatment and monitoring. Secondary endpoint will
be efficacy of HU treatment as measured through the
mean change in fetal hemoglobin (%) at the end of
3 months of HU treatment. Monitoring and safety end-
points will be the proportion of participants experiencing
serious adverse events related to HU at week 2, 6, 10 and
at the end of 3 months of HU treatment and monitoring.
Study setting
The study will be conducted at Muhimbili National
Hospital (MNH), in Dar es Salaam, Tanzania. MNH serves
as the main referral hospital in Tanzania. It houses the
Muhimbili Sickle Cell Clinic that serves on average 30 to
60 patients per week.
Study population
The study population will be drawn from among the ap-
proximately 4000 patients with SCA who are registered at
the Muhimbili Sickle Cell Clinic. The main mDOT-HuA
study inclusion and exclusion criteria are listed in Table 2.
Screening and baseline assessment
This will include the use of database records, interviews
and laboratory assessment. At the first clinic visit (T-12,
Fig. 1), participant’s eligibility will initially be screened based
on data record available from the Muhimbili Sickle Cohort
database (i.e. age, sickle cell status) before further work up
is done. During further screening/and prior randomization,
consenting participants will undergo interviews, laboratory
tests including complete blood counts, reticulocyte count,
alanine transaminase, lactate dehydrogenase, haemoglobin
F, serum creatinine, HIV status, and urine pregnancy test
for women and those eligible (answered yes to all inclusion
criteria and no to all exclusion criteria) will be included in
the trial. The period from enrollment confirmation to the
end of 3-month pre-treatment follow-up/re-screening
(T-12-T0, Fig. 1) will be used to collect baseline data. At
the end of this period, all patients will be re-screened for
eligibility and all those still eligible (n = 100, planned),
(T0, Fig. 1) will enter into the trail.
Randomization, stratification and blinding
A randomization schedule will be generated using a
Research Electronic Data Capture System (REDCap).
Table 1 Previous studies reporting adherence to HU treatment in SCA







Single site, cross sectional 75 (3.5–17.8 years) Visit adherence, Morisky score,
provider report, Pharmacy-refill






153, 9 months–1.5 years 80 % of liquid medication taken











84, 5–15 y ears Pill count 74
Candrilli et al.,
(2011) [4]
Retrospective insurance claims 312, mean age 21 years Medication possession ratio 35
Fig. 1 Stages of the trial, events and time points. Keys: T time in weeks, − before randomization, FU follow-up, * = participants will be enrolled in
2 months but each of them entering at his/her own time and start screening on the same day
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Participants will be stratified by baseline haemoglobin
concentration, just before start of the treatment period
(<6 g/dL versus ≥6 g/dL) and assignment of participants
to treatment arms will be balanced through the use of a
stratified (central) randomization (Fig. 2). This will be an




Participants will receive mobile phones, fixed dose HU
therapy (15 mg/Kg/day) and mDOT consisting of a web
based medication adherence monitoring system that in-
cludes directly video confirmation of adherence using the
patient’s personal cellular telephone (Fig. 2). Participants
will receive alerts on their cell phone at pre-arranged
times to remind them to take their medications. They will
capture a video using their mobile phone of the medica-
tion dose and of themselves and the act of swallowing
HU. The videos will then be uploaded in the WhatsApp
Messenger application (WhatsApp Inc., Mountain View,
CA, USA) and sent to the study mobile phone for storage
in REDCap. Participants will be followed-up at 2 weeks
after initiation of therapy and monthly thereafter.
The standard monitoring (SM) arm
Participants will receive mobile phones and fixed dose
HU therapy (15 mg/Kg/day) with standard monitoring
(Fig. 2). Standard monitoring is defined as a follow-up
visit 2 weeks after initiation of therapy and monthly
follow-ups thereafter.
Clinical assessment
During the pre-treatment phase participants will be evalu-
ated for social demographics, clinical symptoms such as
painful crises, fever, hospital admission, blood transfusion
and measurements of weight, temperature, pulse, and
blood pressure will be obtained. After randomization
participants will have additional assessment of HU drug
adherence and possible adverse drug event.
Laboratory assessment
This will follow the schedule as indicated in Table 3
Laboratory tests
A blood sample (5 ml) will be collected through
venipuncture using a vacutainer needle. Two samples will
be collected at each bleed: 0.5 ml will be collected in an
EDTA tube, well mixed and immediately sent to the
Muhimbili Central Pathology laboratory for full blood
count and reticulocyte count (determined by automated
haematology analyser (Sysmex XT 2000i Kobe, Japan). The
second sample, (4.5 ml) will be collected in a heparinized
tube, immediately sent to the same laboratory, centrifuged
(3000 g for 10 min) and plasma separated into a cryovial
for creatinine, Alanine transaminase and Lactate dehydro-
genase (Cobas Integra 400 Plus Chemistry Analyzer, Roche,
Basel, Switzerland). Haemoglobin F quantification will be
determined by high performance liquid chromatography
(HPLC) (Bio-Rad Variant I, Bio-Rad, Hercules, CA, USA).
Assessment of endpoints
Adherence: Patients will receive a 30-day supply of HU at
each visit during the 3-month treatment period. The study
pharmacist will maintain a drug dispensing and prescrip-
tion record for each patient at the sickle cell clinic. MPR
will be calculated at the end of the 90 days of treatment.
Adherence will be defined as a MPR ≥0.80.
Efficacy: Efficacy will be assessed by measurement of
mean change of hemoglobin F between baseline and the
end of 3 months.
Safety: This is monitored through clinical and laboratory
assessment by determining the frequency of fever, malaria
and any cytopenia (neutropenia, thrombocytopenia etc. as
indicated below in the HU holding and de-escalation criteria;
Table 2 Summary of the inclusion and exclusion criteria at
screening
Inclusion criteria Exclusion criteria
Hemoglobin SS genotype Chronic transfusion program as
defined by participating in a
scheduled (pre-planned) series of
transfusions for prophylactic
purposes or a hemoglobin
A level >20 % of the total
hemoglobin
Age ≥18 years and living in
Dar es Salaam
Haemoglobin <4.0 g/dL
Male or female (post-menopausal,
sterile, or using an acceptable
method of contraception)
HIV positive
Negative urine pregnancy test at
Screening and a negative urine
pregnancy test (dipstick) prior to
randomization and dosing
Female planning to become
pregnant during the study period
Absolute neutrophil count
>1500/uL
Serious mental (including psychosis)
or physical illness, which, in the
opinion of the investigators would
compromise participation in the
study (e.g. impaired mental capacity,
alcoholism)
Platelet count >95,000/uL Any condition which the investigators
judge to preclude safe participation in
the study or to confound the
evaluation of the study outcome
Serum creatinine <100 μmol/L
(1.2 mg/dL)
Alanine transaminase less than
two times the upper limit of
normal
Being able and willing to record
and submit videos electronically.
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monitoring will be captured at week 2, 6, 10 and at the end
of 3 months of HU.
Adherence to follow-up clinics and blood tests
A therapeutic alliance between participants and study
team and this will maximize scheduled study visit attend-
ance. Since regular blood count is critical in HU therapy,
an active follow-up for patients who fail to come for blood
count. If it happen some patients did not report to the
clinic for laboratory assessments within the predefined in-
tervals, they will not receive subsequent HU refills.
Subject withdrawal criteria and procedures
Subjects who experience any of the following cytopenias
while on HU will be instructed to hold the medication,
tested for malaria infection and other intercurrent illnesses
and have a laboratory follow-up in 2 weeks. If at the 2 week
follow up the cytopenia has resolved and the investigators
deem it was due to a transient infectious illness, HU will be
restarted at the dose of 15 mg/Kg. If at the 2-week follow-
up the cytopenia has resolved and the investigators deem it
was due to HU, the subject will receive HU at the de-
escalation dose of 10 mg/Kg for the remainder of the study.
If at the 2 week follow up there is persistent cytopenia, HU
will be stopped and not resumed for the duration of the
study, but the subject will continue to undergo standard
monitoring, regardless of his treatment arm allocation
(Table 4).
Statistical considerations
Sample size: A sample size of 50 patients per group
provided an 80 % power to detect an estimated propor-
tion with HU adherence of 0.35 in the control group
versus 0.65 in the treatment group, assuming a two-
sided type I error rate of 5 % and a 15 % dropout rate.
The 0.35 proportion of adherence to HU is based on a
study done by Candrilli et al. [4].
Table 3 Clinic and laboratory schedule
Clinical/laboratory event Corresponding visit/time schedule
V1 V2 V3 V4 V5 V6 V7 V8 V9 V10
T-12 T-8 T-4 T0 T2 T4 T8 T12 16 T20
Screening √
Visit √ √ √ √ √ √ √ √ √ √
Vitals √ √ √ √ √ √ √ √ √ √
Clinical √ √ √ √ √ √ √ √ √ √
Previous current medication √
Past history √
Physical Examination √ √ √ √ √ √ √ √ √ √
Laboratory Sample Collection √ √ √ √ √ √ √ √ √ √
Inclusion criteria √ √
Abbreviations: V clinic visit, T time in weeks, − before randomization
Fig. 2 Flow chart for study enrollment and randomization. Keys; ALT Alaninie aminotransferase, SM Standard monitoring, MPR Medication
possession ratio
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Statistical analysis: The primary outcome of this study
is adherence to HU as defined as MPR ≥80 at the end of
3 months of HU treatment. The proportions of
adherence in the two arms will be compared by Fisher’s
exact test. A forward, stepwise logistic-regression pro-
cedure will be then performed to adjust raw adherence
difference with use of covariates that will be found to be
significant predictors of outcomes. Covariates will be en-
tered into the logistic model at a P value of ≤0.10.
Sub group analysis: For data analysis, the study
population will be categorized into three groups: the
intention-to treat (ITT), the Per-Protocol (PP) and the safety
populations. These categories will be defined as follows:
ITT: All patients who are randomized and receive at
least 1 supply of HU, and will be analyzed by random-
ized treatment group.
PP: All ITT patients who complete the study, receive
both supplies of HU, and have no major protocol violations
that will impact the efficacy assessments. PP population will
be documented prior to database lock.
Safety: All patients who are randomized and receive at
least 1 supply of HU. Safety population will be analyzed
by actual treatment received.
Discussion
There are no published data on the adherence of HU in
SCA in African settings and no set gold standard to
assess the adherence, effectiveness and efficiency of this
therapy in sub-Saharan Africa. Lanzkron et al. conducted
a systematic review of HU treatment in adults with SCA
and reported that there was a relative increase in HbF
from 45 to 20 %, relative reduction in crisis by 68 to
84 % and hospital admissions declined by 18 to 32 %,
however lack of long term follow-up limited the
conclusion on safety and toxicity [18]. Ware et al. [10]
Thornburg et al. [7] and Kinney et al. [9] conducted
randomized control trials to address HU adherence in
SCA using pill counts, provider report, and pharmacy
refills and found that adherence was 94, 89 and 74 %,
respectively by the three methods. And all these studies
also address a need to conduct of further studies to
address adherence to medications using different age
groups and approach including DOT. The use of mDOT
might have cost implications and patients might only adhere
well to drug during observation and go back to the usual
behaviors afterwards [19] but with the widespread availabil-
ity of smartphones and internet use in developing countries
like Tanzania [20, 21] this technology may have the potential
to overcome some of these barriers. mDOT-HuA study
might shed more light on these challenges and provide
further information on the post-treatment stage of HU use
among individuals with SCA living in Sub Saharan Africa.
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Positive urine pregnancy test
Platelet count <95,000/uL Any cytopenia that does not
resolve after holding HU
for 2 weeks
Hb <9 g/dL with absolute
reticulocyte count <95,000/uL
Request of the subject or proxy
(withdrawal of consent by
the subject)
Investigator’s discretion
Subject is lost to follow-up
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